摘要
目的:观察左西孟旦联合多巴酚丁胺治疗急性失代偿性心力衰竭(ADHF)患者的效果。方法:选取2020年3月至2022年10月该院收治的80例ADHF患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各40例。两组均进行对症治疗,在此基础上,对照组予以多巴酚丁胺治疗,观察组在对照组基础上联合左西孟旦治疗,两组均连续治疗5 d。比较两组临床疗效,治疗前后心功能指标[左心室射血分数(LVEF)、左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)]水平、血清学指标[脑钠肽(BNP)、N末端脑钠肽前体(NT-proBNP)]水平,以及不良反应发生率。结果:观察组治疗总有效率为97.50%(39/40),高于对照组的77.50%(31/40),差异有统计学意义(P<0.05);治疗后,观察组LVEF水平高于对照组,LVEDV、LVESV水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组BNP、NT-proBNP水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:左西孟旦联合多巴酚丁胺治疗ADHF患者可提高治疗总有效率,改善心功能指标水平,降低血清学指标水平,效果优于单纯多巴酚丁胺治疗。
Objective:To observe effects of Levosimendan combined with Dobutamine in treatment of patients with acute decompensated heart failure(ADHF).Methods:A prospective study was conducted on 80 patients with ADHF admitted to this hospital from March 2020 to October 2022.According to the random number table method,they were divided into control group and observation group,40 cases in each group.Both groups were given symptomatic treatment.On this basis,the control group was treated with Dobutamine,while the observation group was treated with Levosimendan on the basis of that of the control group.Both groups were treated for 5 d.The clinical efficacy,the cardiac function indexes [left ventricular ejection fraction(LVEF),left ventricular end-diastolic volume(LVEDV),left ventricular end-systolic volume(LVESV)] levels and the serological indexes [brain natriuretic peptide(BNP),N-terminal brain natriuretic peptide precursor(NT-proBNP)] levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 97.50%(39/40),which was higher than 77.50%(31/40) of the control group,and the difference was statistically significant(P<0.05).After the treatment,the level of LVEF in the observation group was higher than that in the control group,the levels of LVEDV and LVESV were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of BNP and NT-proBNP in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Levosimendan combined with Dobutamine in the treatment of the ADHF patients can improve the total effective rate of treatment,improve the levels of cardiac function indexes,and reduce the levels of serological indexes.Moreover,it is superior to single Dobutamine tr
作者
黄春华
HUANG Chunhua(Department of Cardiology of Suichuan County People’s Hospital,Ji’an 343900 Jiangxi,China)
出处
《中国民康医学》
2024年第6期20-22,共3页
Medical Journal of Chinese People’s Health
